MONITOR-PsA (n=218): •36.5% had >1 csDMARD •Of those, 49.2% tried combination (combo) csDMARDs •63.6% of combo csDMARD users in MDA at 48wks •61.1% stopped due to side effects—not inefficacy Real-world support for csDMARD combos where biologics delayed. Abstract#OP0093 https://t.co/3Anme39VXk